Medical Cannabis Research
This 2004 study by Ethan Russo, published in the journal Neuroendocrinology, examines the concept of clinical endocannabinoid deficiency and the prospect that it could underlie the pathophysiology of migraine, fibromyalgia, irritable bowel syndrome and other functional conditions alleviated by clinical cannabis.
This study, published in the June 2014 issue of the Journal of Clinical Psychopharmacology, describes more than 100 patients reporting about the therapeutic satisfaction with their pharmaceutical-grade cannabis product. Furthermore, differences in subjective effects among the available strains are investigated.
Published in the British Journal of Cancer in 2006, these scientists reported ‘the first clinical study aimed at assessing cannabinoid antitumoral action, specifically a pilot phase I trial in which nine patients with recurrent glioblastoma multiforme were administered THC intratumoraly. The patients had previously failed standard therapy (surgery and radiotherapy) and had clear evidence of tumour progression’.
Mental health and suicide rates – this discussion paper published in 2012, states, “Our results suggest that the passage of a medical marijuana law is associated with an almost 5 percent reduction in the total suicide rate, an 11 percent reduction in the suicide rate of 20- through 29-year-old males, and a 9 percent reduction in the suicide rate of 30- through 39-year-old males.”
This 2014 study out of Japan indicated that genetic traits, specifically the CB1 receptor gene genotypes, are closely related to happiness. C allele carriers of the SNP of CNR1 who are sensitive to positive emotional stimuli may experience a higher magnitude pleasure response when they experience positive events and may have a higher subjective happiness level.